How do I find recruiting Acute Lymphoblastic Leukemia clinical trials?

Corterve aggregates actively recruiting Acute Lymphoblastic Leukemia studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.

Are Acute Lymphoblastic Leukemia clinical trials free to join?

Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.

Who can take part in a Acute Lymphoblastic Leukemia clinical trial?

Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.

Acute Lymphoblastic Leukemia Clinical Trials

Acute Lymphoblastic Leukemia clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for acute Lymphoblastic Leukemia. Corterve aggregates actively recruiting Acute Lymphoblastic Leukemia studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.

Browse all Acute Lymphoblastic Leukemia trials Take the free assessment

Recruiting Acute Lymphoblastic Leukemia studies

Personalized NK Cell Therapy in CBT
NCT02727803PHASE2M.D. Anderson Cancer CenterHouston, Texas
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
NCT05621291NANational Cancer Institute (NCI)Los Angeles, California
Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia
NCT07191119NASt. Jude Children's Research HospitalMemphis, Tennessee
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
NCT05442515PHASE1, PHASE2National Cancer Institute (NCI)Bethesda, Maryland
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
NCT07586618PHASE1Allterum Therapeutics, IncAurora, Colorado
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
NCT06287944PHASE1City of Hope Medical CenterDuarte, California
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
NCT07020533PHASE1City of Hope Medical CenterDuarte, California
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
NCT03779854PHASE2Fred Hutchinson Cancer CenterLos Angeles, California
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157PHASE2National Cancer Institute (NCI)Birmingham, Alabama
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06317662PHASE2National Cancer Institute (NCI)Birmingham, Alabama
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
NCT03739814PHASE2National Cancer Institute (NCI)Birmingham, Alabama
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103PHASE1, PHASE2Merck Sharp & Dohme LLCLos Angeles, California

See all 136 recruiting Acute Lymphoblastic Leukemia trials →

Acute Lymphoblastic Leukemia trials by state

Acute Lymphoblastic Leukemia trials by metro

Frequently asked questions

How do I find recruiting Acute Lymphoblastic Leukemia clinical trials?: Corterve aggregates actively recruiting Acute Lymphoblastic Leukemia studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.
Are Acute Lymphoblastic Leukemia clinical trials free to join?: Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.
Who can take part in a Acute Lymphoblastic Leukemia clinical trial?: Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.